Recherches "plusieurs pathologies"
EXPRESS
Low level of genomic alteration to predict exceptional and unexpected response to targeted thÚrapies in patients with solid tumors.;EXPRESS : EXcePtional RESponSe
Paris
CHRISTOPHE LE TOURNEAU
Gynécologie
GM102
OPEN, NON CONTROLLED, MULTICENTER, FIRST-IN-HUMAN STUDY FOR THE EVALUATION OF THE SAFETY, PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF GM102 IN PATIENTS WITH ADVANCED PRETREATED GYNECOLOGICAL CANCER
Paris
CHRISTOPHE LE TOURNEAU
Gynécologie
ASCORDIA01
ADNEXMR Scoring System: Impact of an MR Scoring System on Therapeutic Strategy of Pelvic Adnexal Masses
Paris, Saint-Cloud
CAROLINE MALHAIRE, ROMAN ROUZIER
Recherches "plusieurs pathologies"
CA209-848
A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
Paris
EMANUELA ROMANO
Appareil Digestif
SCARCE (C17-02 PRODIGE 60)
A Non-comparative Randomized 2:1 Phase II Study of Docetaxel, Cisplatin, and 5-fluorouracil in Combination or Not With Atezolizumab in Patients With Metastatic or Unresectable Locally Advanced Squamous Cell Anal Carcinoma
Paris
Appareil Digestif
AAS-Lynch
Assessment of the Effect of a Daily Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome
Paris, Saint-Cloud
BRUNO BUECHER